Epoetin beta (rINN) /ɛˈp.ɪtɪn/ is a synthetic, recombinant[2] form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.

Epoetin beta
Clinical data
Trade namesNeoRecormon, Betapoietin, others[1]
AHFS/Drugs.comInternational Drug Names
License data
Routes of
Intravenous, subcutaneous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
CAS Number
  • none
 ☒N☑Y (what is this?)  (verify)

Epoetin beta is marketed under the trade name NeoRecormon, among others.[3]


Epoetin beta is a recombinant form of human erythropoietin which is produced in Chinese hamster ovary cells. It has the same protein sequence as natural human erythropoietin, being composed of 165 amino acids with about 30 KDa molecular weight.[4]


Erythropoietin (EPO) is a hormone produced in the kidneys. The existence of this hormone has been known since 1906, when scientists first started isolating it, and since the 1980s, a recombinant version of the hormone has been available for use in medical treatment.[citation needed]

See alsoEdit


  1. ^ Centers for Medicare and Medicaid Services: Erythrocyte Stimulating Agents. Accessed 15 February 2017.
  2. ^ Dunn CJ, Markham A (1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs. 51 (2): 299–318. doi:10.2165/00003495-199651020-00008. PMID 8808169.
  3. ^ Amgen - Products. URL: http://www.amgen.com/patients/prca.html Archived 2007-10-28 at the Wayback Machine. Accessed 21 October 2007.
  4. ^ Medsafe: NeoRecormon Datasheet

External linksEdit